CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRPαFc is enhanced in the presence of daratumumab. Specific combinations include SIRPαFc forms that comprise an Fc that is either IgG1 o...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English |
Published |
11.02.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRPαFc is enhanced in the presence of daratumumab. Specific combinations include SIRPαFc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas. |
---|---|
Bibliography: | Application Number: US201916979707 |